Mehta Analysis: Shaming Biopharma Managers
Executive Summary
Shame has historically been used as an effective tool in bringing about a change in pricing policy within an industry. But could it be wielded against the pharma industry today? Viren Mehta, founding partner of Mehta Partners, LLC, considers.
You may also be interested in...
Mehta Analysis: How Relevant Is Traditional Pharma In Sustainable Healthcare?
What will the healthcare industry look like over the next generation – and what role should biopharma industry managers imagine for their sustainable success? Viren Mehta, founding partner of Mehta Partners, LLC, explores the challenges for pharma companies.
Mehta Analysis: The Promise Of 2021
Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.
Mehta Analysis: Biopharma 3.0 – An Industry Society Could Cherish
As it enters a potentially golden decade, can biopharma seize the opportunity to overhaul its business model – and its reputation? Viren Mehta of Mehta Partners LLC discusses.